Rosuvastatin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV Infections

Conditions

HIV Infections, Hyperlipidemia

Trial Timeline

Apr 1, 2004 → Jul 1, 2005

NCT ID

NCT00184951

About Rosuvastatin

Rosuvastatin is a phase 2 stage product being developed by AstraZeneca for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00184951. Target conditions include HIV Infections, Hyperlipidemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00160745	Phase 2	Completed	—	Sep 1, 2006	Hypercholesterolemia
NCT04846231	Phase 2	Completed	Apr 23, 2021	Jul 19, 2022	Hypercholesterolemia
NCT02561845	Pre-clinical	Withdrawn	Oct 1, 2015	Oct 1, 2015	PCI Patients
NCT02484027	Approved	UNKNOWN	Sep 1, 2015	Sep 1, 2018	Infarction, Anterior Cerebral Artery
NCT02077257	Approved	UNKNOWN	Mar 1, 2014	May 1, 2016	Acute Coronary Syndrome
NCT01837823	Phase 2	Completed	Jul 1, 2013	Apr 1, 2015	Obstructive Coronary Artery Disease
NCT01490398	Approved	Completed	Dec 1, 2011	Oct 1, 2013	Hypertension
NCT01364220	Phase 3	Terminated	Aug 1, 2010	Apr 1, 2013	Stroke
NCT00815659	Approved	Completed	Dec 1, 2008	Mar 1, 2010	Metabolic Syndrome
NCT00747149	Approved	Completed	May 1, 2008	Aug 1, 2009	Type 2 Diabetes
NCT00473655	Approved	Completed	Jan 1, 2007	Feb 1, 2009	Hypertriglyceridemia
NCT00335699	Approved	Completed	Aug 1, 2005	Jan 1, 2007	Hypercholesterolemia
NCT00184951	Phase 2	Completed	Apr 1, 2004	Jul 1, 2005	HIV Infections
NCT00240305	Phase 3	Completed	Apr 1, 2004	May 1, 2006	Metabolic Syndrome
NCT00176332	Phase 2	Completed	Mar 1, 2004	Dec 1, 2006	Heart Failure
NCT00228514	Phase 3	Completed	Feb 1, 2004	Jul 1, 2007	Rosuvastatin
NCT00240266	Phase 3	Completed	Aug 1, 2003	Dec 1, 2004	Metabolic Syndrome
NCT00241488	Phase 3	Completed	Jun 1, 2003	Feb 1, 2007	Hypercholesterolemia
NCT00660764	Pre-clinical	Completed	May 1, 2003	Apr 1, 2005	Hypercholesterolemia
NCT00239681	Phase 3	Terminated	Feb 1, 2003	Sep 1, 2008	Elevated High-sensitivity C-Reactive Protein (hsCRP)

Competing Products

20 competing products in HIV Infections

See all competitors

Product	Company	Stage	Hype Score
AAVLP-HPV + Placebo	2A Pharma	Phase 1	25
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	33
VN-0200	Daiichi Sankyo	Phase 2	52
Micafungin	Astellas Pharma	Pre-clinical	23
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	85
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Pre-clinical	23
Micafungin	Astellas Pharma	Phase 1	33
Micafungin + Placebo	Astellas Pharma	Phase 3	77
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Xeruborbactam Oral Prodrug + Ceftibuten	Shionogi	Phase 1	33
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
GW810781	Shionogi	Phase 2	52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
Cefiderocol	Shionogi	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved